BCL6 (EP278) Rabbit Monoclonal

BCL6 is a transcriptional regulator gene which codes for a 706-amino-acid nuclear zinc finger protein. Antibodies to this protein stain the germinal center cells (benign and malignant) in lymphoid follicles, and interfollicular malignant cells in follicular lymphoma, diffuse large B-cell lymphomas, and Burkitt lymphoma, as well as the majority of tumor cells in nodular lymphocyte predominant Hodgkin lymphoma.1-3 Anti-BCL6 rarely stains mantle cell lymphoma and mucosa associated lymphoid tissue (MALT) lymphoma.2 BCL6 expression is seen in approximately 68% of ALK+ anaplastic large cell lymphomas (ALCL) and 28% of ALK- ALCL, NK/T-cell lymphoma (27%), peripheral T-cell lymphoma, NOS (8.6%), and T-lymphoblastic lymphoma (9.1%).4 BCL6 expression can also be observed in angioimmunoblastic T-cell lymphoma (66%-96%).

BCL6 is protected by U.S. patents 6,174,997 and 6,783,94 (Cancer Genetics, Inc.)


  • Reactivity: paraffin
  • Visualization: nuclear
  • Control: tonsil
  • Isotype: IgG
  • Dilution Range: 1:100-1:500*


  1. Garcia JF, et al. Genetic immunization: a new monoclonal antibody for the detection of BCL-6 protein in paraffin sections. J Histochem Cytochem. 2006; 54:31-8.
  2. Dogan A, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol. 2000; 24:846-852.
  3. Kraus MD, et al. Lymphocyte predominance Hodgkin’s disease: the use of Bcl-6 and CD57 in diagnosis and differential diagnosis. AM J Surg Pathol. 2000; 24:1068-78.
  4. Carbone A, et al. BCL-6 Protein expression in human peripheral T-cell neoplasms is restricted to CD30+ anaplastic large-cell lymphomas. Blood. 1997; 90:2445-2450.
  5. Carbone A, et al. Differential expression of BCL-6, CD138/syndecan-1, and Epstein-Barr virus-encoded latent membrane protein-1 identifies distinct histogenetic subsets of acquired immunodeficiency syndrome-related non-Hodgkin’s lymphomas. Blood. 1998; 91:747-55.

Tags: , ,

Category: Antibody